Cathie Wood’s $ARK Invest bought 283,022 shares of CoreWeave stock on November 12, 2026, as the shares fell after an earnings-driven rally. The purchase, worth roughly $16 million to $17 million depending on the pricing basis, came on the same day $ARK sold about $10 million worth of Palantir Technologies stock and $4.2 million in Amazon shares.
Key takeaways
- $ARK added CoreWeave shares after a 6.9% decline.
- CoreWeave raised its 2026 revenue outlook to between $13 billion and $13.3 billion.
- Palantir beat earnings estimates, but growth in contract value slowed.
- $ARK also bought stocks in biotechnology, aviation and defense.
ARK Invest adds CoreWeave stock after sharp price swings
$ARK divided its CoreWeave purchase between the ARKK and ARKW funds. The stock fell 6.9% on November 12, following a 24.7% jump on November 11 after the company reported its third-quarter results.
CoreWeave reported quarterly revenue of $3.66 billion, up 168% from a year earlier. It raised its 2026 revenue forecast to between $13 billion and $13.3 billion, and lifted its year-end annual recurring revenue outlook to between $20 billion and $21 billion. Its backlog reached $132.5 billion.
The company also forecast adjusted operating income of between $1.275 billion and $1.375 billion. Analysts surveyed by Visible Alpha expected $1.07 billion, while analysts polled by LSEG had forecast 2026 revenue of $12.86 billion.
Alongside those projections, CoreWeave expects to collect $9 billion in customer prepayments and deposits within the next three months. CEO Michael Intrator said the funding would help finance the buildout and scaling of the AI infrastructure and software customers require. Contract-backed financing was also cited as another way to support growth.
Earnings news leads to Palantir and Amazon sales
On November 12, $ARK sold 58,339 Palantir shares through its ARKK and ARKW funds, in a transaction worth roughly $10 million. The sale followed the company’s report of results that beat both revenue and adjusted-earnings projections.
Palantir’s third-quarter revenue rose 96% to $2.31 billion, topping the Wall Street consensus of $2.18 billion. Adjusted earnings were $0.44 per share, compared with the $0.41 forecast.
Palantir raised its 2026 revenue guidance to approximately $8.53 billion, implying annual growth of roughly 91%. But total contract value rose only 6% to $2.92 billion, down from 49% growth in the previous quarter. Its shares had declined nearly 18% over the past month.
$ARK’s Amazon sales included 15,941 shares through ARKK on November 12, worth about $4.2 million. Along with 10,968 shares sold on November 10, the transactions totaled 26,909 shares worth about $7.3 million.
Other purchases include biotech, aviation and defense stocks
$ARK’s November 12 purchases also included shares of Twist Bioscience, Archer Aviation, Kratos Defense & Security Solutions, Rocket Lab and Scribe Therapeutics.
Through ARKK and ARKG, the firm bought 72,834 Twist Bioscience shares for $8.93 million. It also purchased 180,561 Archer Aviation shares across three funds for $877,526, extending a week of buying.
Other purchases included 46,521 Kratos Defense & Security Solutions shares worth $1.71 million, 15,114 Rocket Lab shares valued at approximately $1 million, and 39,090 Scribe Therapeutics shares costing $659,057.
TipRanks data gives Amazon a Strong Buy consensus, while CoreWeave and Palantir have Moderate Buy ratings. Based on average analyst price targets, implied upside is 83.9% for CoreWeave, 33.5% for Palantir and 21.5% for Amazon.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.
